Is Intravenous Administration of Iodixanol Associated with Increased Risk of AKI, Dialysis, or Mortality?

pubs.rsna.org November 10, 2017

Among patients at the highest perceived risk of post-contrast Acute Kidney Injury (AKI), intravenous administration of iodixanol for contrast material enhanced CT was not an independent risk factor for AKI, dialysis, or mortality. A total of 5758 patients (1538 with stage 1–2 CKD, 2899 with stage 3 CKD, and 1321 with stage 4–5 CKD) were included in the study. After propensity score adjustment, rates of AKI, dialysis, and mortality were not significantly higher in the IOCM group compared with the noncontrast group for all CKD subgroups (AKI odds ratios [ORs], 0.74–0.91, P = .16–0.69; dialysis ORs, 0.74–2.00, P = .42–.76; mortality ORs, 0.98–1.24, P = .39–.88). Sensitivity analyses yielded similar results.